Today in a Senate Health, Education, Labor and Pensions Committee hearing, U.S. Senator Josh Hawley (R-Mo.) secured a commitment from Health and Human Services Secretary Robert F. Kennedy (RFK) Jr. that he would review ‘alarming’ new data on the chemical abortion drug mifepristone. RFK Jr. also stated that in light of the new data, the Food and Drug Administration (FDA) label for mifepristone should change to accurately reflect the adverse effects of the drug.
“You’ve previously testified to the committee that you would do a top-to-bottom review of mifepristone,” said Senator Hawley. “Do you continue to stand by that, and don’t you think this new data shows that the need to do a full review is indeed pressing?”
“It’s alarming, and it indicates that at the very least, the label should be changed,”RFK said regarding the new mifepristone data. “I’ve asked Marty Makary at the FDA to do a complete review and report back.”
RFK Jr. also promised he would submit his own recommendation to President Trump based on the data. This exchange comes after Senator Hawley has advocated for reinstating safety guardrails surrounding mifepristone since the new study was released, from introducing legislation to urging the Department of Justice to reconsider its defense of the Biden Administration’s policy on mifepristone.
In the same hearing, Senator Hawley also questioned RFK Jr. on his stance towards tax breaks for Big Pharma’s television deals, prompting RFK Jr. to pledge his support for Senator Hawley’s bipartisan, bicameral bill cracking down on Big Pharma’s sweetheart deals.
Watch the full hearing here.
###